Ketamine Infusion for Symptomatic Improvement in Severe Borderline Personality Disorder
Key facts
- Who runs it
- University Hospital, Toulouse
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 38 people, planned
- Starts
- 1 Jan 2027
- Expected to end
- 30 Sept 2029
- Type of study
- Interventional
- Treatments tested
- IV Ketamine (0.5 mg/kg) Infusion - Two Doses Administered 24 Hours Apart for Severe Borderline Personality Disorder
- Record updated
- 4 November 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Adult patient aged 18 to 65 years
- Fluent in French
- Person affiliated with or receiving social security benefits
- Diagnosis of borderline personality disorder established according to the DSM-5 MINI criteria (5 out of 9 criteria)
- Severe borderline personality disorder
- Patient receiving stable pharmacological (antipsychotic, mood stabilizer, antidepressant) and/or non-pharmacological (schema therapy, DBT) treatment for four weeks
Who cannot take part
- New long-term treatment introduced within the previous four weeks (antidepressant, antipsychotic, mood stabilizer)
- Personal history of an acute psychotic episode or chronic psychotic disorder
- Personal history of a manic or hypomanic episode
- Family history (first-degree relatives) of a psychotic disorder
- Prescription of an Monoamine oxidase inhibitors (increased risk of hypertension)
- History of cirrhosis or major liver function test abnormalities
- Current severe depressive episode
- Recreational ketamine use (multi-weekly ketamine use)
- Specific absolute contraindication to ketamine
- Major ECG abnormality
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The main objective of this pilot study is to evaluate at D9 the evolution of BPD symptoms' intensity(scale BSL-23) in severe BPD patients, after two Ketamine infusions (0.5mg/kg at H0 and H24). The intervention is combined with the first level standard of care : Good Psychiatric Management (GPM). Patients are followed up to 3 months by regular visits conducted by a psychiatrist. Secondary outcomes are monitored including BPD symptoms at different times, suicidal ideation, depressiv symptoms, healthcare use and adverse effects.
The group in the trial
- IV Ketamine Double Infusion (0.5 mg/kg) for Severe Borderline Personality DisorderTreatment being tested
Treatment: IV Ketamine (0.5 mg/kg) Infusion - Two Doses Administered 24 Hours Apart for Severe Borderline Personality Disorder
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Ketamine Infusion for Symptomatic Improvement in Severe Borderline Personality Disorder: A Pilot Study
- Fit questions
- Built from NCT07099534, who can take part
- Record updated
- 4 November 2026